Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
äŒæ¥ã³ãŒãCABA
äŒç€ŸåCabaletta Bio Inc
äžå Žæ¥Oct 25, 2019
æé«çµå¶è²¬ä»»è
ãCEOãNichtberger (Steven)
åŸæ¥å¡æ°161
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 25
æ¬ç€Ÿæåšå°2929 Arch Street
éœåžPHILADELPHIA
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19104
é»è©±çªå·12677593100
ãŠã§ããµã€ãhttps://www.cabalettabio.com/
äŒæ¥ã³ãŒãCABA
äžå Žæ¥Oct 25, 2019
æé«çµå¶è²¬ä»»è
ãCEOãNichtberger (Steven)